View Item 

Show simple item record

The use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessment
dc.contributor.authorPitt, Bertram
dc.contributor.authorZannad, Faiez
dc.date.accessioned2024-02-02T14:47:05Z
dc.date.available2025-01-02 09:47:04en
dc.date.available2024-02-02T14:47:05Z
dc.date.issued2023-12
dc.identifier.citationPitt, Bertram; Zannad, Faiez (2023). "The use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessment." European Journal of Heart Failure 25(12): 2174-2176.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/192222
dc.publisherJohn Wiley & Sons, Ltd.
dc.titleThe use of mineralocorticoid receptor antagonists for patients with heart failure with a reduced ejection fraction: A time for reassessment
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/192222/1/ejhf3091.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/192222/2/ejhf3091_am.pdf
dc.identifier.doi10.1002/ejhf.3091
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceZannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11 – 21.
dc.identifier.citedreferenceMcDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4 – 131. https://doi.org/10.1002/ejhf.2333
dc.identifier.citedreferenceHeidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895 – e1032. https://doi.org/10.1161/CIR.0000000000001063
dc.identifier.citedreferencePatel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, et al. Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 2021; 78: 330 – 343. https://doi.org/10.1016/j.jacc.2021.05.002
dc.identifier.citedreferenceJuurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543 – 551. https://doi.org/10.1056/NEJMoa040135
dc.identifier.citedreferenceGuidetti F, Lund LH, Benson L, Hage C, Musella F, Stolfo D, et al. Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry. Eur J Heart Fail 2023; 25: 2164 – 2173. https://doi.org/10.1002/ejhf.3049
dc.identifier.citedreferenceFerreira JP, Zannad F, Butler J, Filipattos G, Ritter I, Schüler E, et al. Empagliflozin and serum potassium in heart failure: An analysis from EMPEROR-Pooled. Eur Heart J 2022; 43: 2984 – 2993. https://doi.org/10.1093/eurheartj/ehac306
dc.identifier.citedreferenceDesai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: A secondary analysis of the PARADIGM-HF trial. JAMA Cardiol 2017; 2: 79 – 85. https://doi.org/10.1001/jamacardio.2016.4733
dc.identifier.citedreferenceAronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol 2003; 91: 245 – 248. https://doi.org/10.1016/s0002-9149(02)03119-3
dc.identifier.citedreferenceStaessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457 – 465. https://doi.org/10.1016/s0002-9149(02)03119-3
dc.identifier.citedreferenceFerreira JP, Pitt B, McMurray JJV, Pocock SJ, Solomon SD, Pfeffer MA, et al. Steroidal MRA across the spectrum of renal function: A pooled analysis of RCTs. JACC Heart Fail 2022; 10: 842 – 850. https://doi.org/10.1016/j.jchf.2022.06.010
dc.identifier.citedreferenceBakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 dia. N Engl J Med 2020; 383: 2219 – 2229. https://doi.org/10.1056/NEJMoa2025845
dc.identifier.citedreferencePitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021; 385: 2252 – 2263. https://doi.org/10.1056/NEJMoa2110956
dc.identifier.citedreferenceVerma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J 2022; 43: 3781 – 3791. https://doi.org/10.1093/eurheartj/ehac352
dc.identifier.citedreferenceIbarrola J, Lu Q, Zennaro MC, Jaffe IZ. Mechanism by which inflammation and oxidative stress induce mineralocorticoid receptor gene expression in aging vascular smooth muscle cells. Hypertension 2023; 80: 111 – 124. https://doi.org/10.1161/HYPERTENSIONAHA.122.19213
dc.identifier.citedreferencePitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med 1999; 341: 709 – 717. https://doi.org/10.1056/NEJM199909023411001
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf3091.pdf
Size:
235.9KB
Format:
PDF
View/Open
Name:
ejhf3091_am.pdf
Size:
210.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.